Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Legendary Short Seller Jim Chanos Is Bullish On These Equities

Kynikos, the hedge fund of revered short seller Jim Chanos, recently disclosed its U.S public equity portfolio as of September 30, which contained assets worth $309.52 million as of that date. According to the filing, Kynikos sold its entire stake in 31 stocks during the third quarter, while reducing its holding in 24 stocks, making additional purchases in 15 stocks, and initiated a stake in six stocks. The filing also revealed that the fund’s equity portfolio had a very high quarterly turnover rate of 82.22% during the third quarter and that it became considerably top-heavy by the end of that period, with Kynikos’ top-10 equity holdings amassing nearly three-fourths of its portfolio’s value.

In this article, we are going to discuss five stocks that Chanos and his fund Kynikos are bullish on as of the end of the third quarter.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

Jim Chanos puppeteer

#5 Crown Holdings, Inc. (NYSE:CCK)

– Shares Held By Kynikos (as of September 30): 76,473

– Value of The Holding (as of September 30): 4.36 Million

Let’s start with Crown Holdings, Inc. (NYSE:CCK), in which Kynikos reduced its stake by 42% during the third quarter. Shares of the consumer goods packaging products company have had a slow but steady run upwards over the last five years, appreciating by 75.58% during that period. Although the stock has corrected a little in this quarter, it is still trading up by 8.15% in 2016. For its most recent quarter, Crown Holdings, Inc. (NYSE:CCK) reported EPS of $1.33, which was $0.03 above analysts’ expectations. However, the revenue of $2.33 billion that it declared for the period missed estimates by $60 million. On October 24, analysts at Jefferies Group reiterated their ‘Buy’ rating on the stock, but lowered their price target on it to $63 from $64, suggesting potential upside of 15%.

Follow Crown Holdings Inc (NYSE:CCK)
Trade (NYSE:CCK) Now!

#4 Apple Inc. (NASDAQ:AAPL)

– Shares Held By Kynikos (as of September 30): 39,238

– Value of The Holding (as of September 30): 4.44 Million

Kynikos lowered its stake in Apple Inc. (NASDAQ:AAPL) marginally, by 2%, during the September quarter. Apple Inc. (NASDAQ:AAPL)’s stock suffered a significant decline in the days following the company’s third quarter earnings release and is currently trading up by only 5.67% year-to-date.  According to recent reports, after billionaire Donald Trump was elected as the new President, the company has been toying with the idea of moving some of its iPhone production back to the United States, presumably to appease the President-elect. However, analysts think that it’s highly unlikely that the company will go ahead with that move unless trade relations between the U.S. and China suffer a dramatic breakdown. On the contrary, a few analysts consider Mr. Trump’s win to be favorable for the company, due to the fact that if he goes ahead with his promises, it will end up paying less taxes and will be able to bring the $200 billion that it holds overseas back to the United States.

Follow Apple Inc (NASDAQ:AAPL)
Trade (NASDAQ:AAPL) Now!

We’ll check out three more stocks that Jim Chanos is bullish on over on the next page.

#3 Starz (NASDAQ:STRZA)

– Shares Held By Kynikos (as of September 30): 166,666

– Value of The Holding (as of September 30): 5.2 Million

Moving on, Kynikos increased its holding in Starz (NASDAQ:STRZA) by 15% during the third quarter. Jeffrey Jacobowitz’s Simcoe Capital Management was another hedge fund that we track which boosted its stake in the company during that time, by 7% to 924,875 shares. After months of negotiations, Lions Gate Entertainment Corp. (USA) (NYSE:LGF) announced on June 30 that it would be acquiring Starz (NASDAQ:STRZA) in a $4.4 billion cash and stock deal. Since that announcement, Starz’s stock has been on an upward march. Even Mr. Trump’s recent victory, which was considered detrimental for media companies that are currently engaged in M&A deals, hasn’t caused the stock to pull back, as it now trades up by 1.16% year-to-date. At the end of last month, analysts at Stifel Nicolaus upgraded the stock to ‘Buy’ from ‘Hold’ and also upped their price target on it to $36 from $33.

Follow Starz Acquisition Llc (NASDAQ:STRZA)
Trade (NASDAQ:STRZA) Now!

#2 Molson Coors Brewing Co (NYSE:TAP)

– Shares Held By Kynikos (as of September 30): 51,833

– Value of The Holding (as of September 30): 5.7 Million

Amid a 7.5% rise in Molson Coors Brewing Co (NYSE:TAP)’s stock during the third quarter, Kynikos upped its stake in the company by 14%. Shares of the brewing company have fallen quite a bit since making their lifetime high of $112.09 last month, but still boast year-to-date gains of 5.32%. On November 17, Molson Coors Brewing Co (NYSE:TAP) declared a quarterly dividend of $0.41 per share, which based on the current price of the stock translates into a forward yield of 1.66%. For its fiscal 2016 third quarter, the company reported EPS of $1.03 on revenue of $947.50 million, which was below analysts’ estimates of EPS of $1.05 on revenue of $985.75 million. Nevertheless, most analysts continue to remain bullish on the stock, with an average rating of ‘Buy’ and an average price target of $124.60 on it.

 – Related Reading: 10 Largest Alcohol Companies in the World

#1 SPDR S&P MidCap 400 ETF (NYSEARCA:MDY)

– Shares Held By Kynikos (as of September 30): 220,762

– Value of The Holding (as of September 30): 62.31 Million

After boosting its holding in the SPDR S&P MidCap 400 ETF (NYSEARCA:MDY) by 445% during the second quarter, Kynikos increased it by a further 25% during the third quarter. The SPDR S&P MidCap 400 ETF (NYSEARCA:MDY) tracks and seeks to provide investment results that mimic the price and yield performance of the S&P MidCap 400 Index, before expenses. In the last five years, the ETF has appreciated by over 90% and is currently trading at its lifetime high of $297.86. A large part of the gains that the ETF has registered this year have come on the back of the recent rally in the equity markets after Mr. Trump’s win. At the end of October, the ETF had a 12-Month yield of 1.38% and was rated Bronze by Morningstar due to a relatively higher fee than its closest competitors and disadvantageous structure limit.

Follow Spdr S & P Midcap 400 Etf Trust (NYSEARCA:MDY)
Trade (NYSEARCA:MDY) Now!

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...